Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C47H51NO14 |
Molecular Weight | 853.9061 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 11 / 11 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7
InChI
InChIKey=RCINICONZNJXQF-MZXODVADSA-N
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
DescriptionSources: http://www.drugbank.ca/drugs/DB01229Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf and https://www.ncbi.nlm.nih.gov/pubmed/18068131
Sources: http://www.drugbank.ca/drugs/DB01229
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf and https://www.ncbi.nlm.nih.gov/pubmed/18068131
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. Taxol is marketed for the treatment of Breast cancer; Gastric cancer; Kaposi's sarcoma; Non-small cell lung cancer; Ovarian cancer. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer. Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12056715
Curator's Comment: No or negligible penetration of paclitaxel over an intact blood– brain barrier
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: HeLa cell growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/27095936 |
7.08 µM [IC50] | ||
Target ID: SKOV3 breast cancer cell growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/27599579 |
38.7 nM [IC50] | ||
Target ID: GO:0046785 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8555181 |
23.0 µM [EC50] | ||
Target ID: CHEMBL1915 Sources: http://www.drugbank.ca/drugs/DB01229 |
|||
Target ID: CHEMBL4860 Sources: http://www.drugbank.ca/drugs/DB01229 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TAXOL Approved UseTAXOL is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. Launch Date8.9907842E11 |
|||
Primary | TAXOL Approved UseTAXOL is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Launch Date8.9907842E11 |
|||
Primary | TAXOL Approved UseTAXOL, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Launch Date8.9907842E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.92 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8664192 |
250 mg/m² steady-state, intravenous dose: 250 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
PACLITAXEL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.5 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7799018 |
175 mg/m² steady-state, intravenous dose: 175 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
PACLITAXEL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27.07 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8664192 |
250 mg/m² steady-state, intravenous dose: 250 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
PACLITAXEL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7799018 |
175 mg/m² steady-state, intravenous dose: 175 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
PACLITAXEL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.5% |
PACLITAXEL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
135 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 135 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 135 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Anaphylaxis, Dyspnea... Other AEs: Anaphylaxis (2%) Sources: Dyspnea (severe, 2%) Hypotension (severe, 2%) Generalized urticaria (severe, 2%) Angioedema (severe, 2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anaphylaxis | 2% | 135 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 135 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 135 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Angioedema | severe, 2% | 135 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 135 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 135 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Dyspnea | severe, 2% | 135 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 135 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 135 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Generalized urticaria | severe, 2% | 135 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 135 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 135 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Hypotension | severe, 2% | 135 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 135 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 135 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.jci.org/articles/view/15451 Page: - |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21660_ABRAXANE_biopharmr.PDF#page=20 Page: 20.0 |
major | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21660_ABRAXANE_biopharmr.PDF#page=20 Page: 20.0 |
minor | |||
Page: - |
no | |||
Page: - |
yes [Km 6.79 uM] | |||
Page: - |
yes | |||
Sources: https://www.nature.com/articles/tpj201013 Page: - |
yes | |||
Sources: https://www.jci.org/articles/view/96160 Page: - |
yes | |||
Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Biochemical properties of a minimal functional domain with ATP-binding activity of the NTPase/helicase of hepatitis C virus. | 1999 Dec |
|
Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. | 1999 Dec |
|
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. | 1999 Feb |
|
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. | 1999 Mar |
|
Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. | 1999 Mar 19 |
|
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. | 1999 Nov |
|
Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel. | 1999 Oct |
|
Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine and taxol--in vitro explant study. | 1999 Oct 22 |
|
Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. | 2000 Apr |
|
Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. | 2000 Apr |
|
Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity. | 2000 Apr |
|
Microtubules, but not actin filaments, drive daughter cell budding and cell division in Toxoplasma gondii. | 2000 Apr |
|
Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. | 2000 Aug |
|
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies. | 2000 Aug |
|
Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. | 2000 Dec 1 |
|
Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. | 2000 Jan |
|
Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. | 2000 Jan 28 |
|
Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. | 2000 Jul 1 |
|
Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. | 2000 Jun |
|
Biochemical mechanism of cross-resistance to paclitaxel in a mitomycin c-resistant human bladder cancer cell line. | 2000 Mar 31 |
|
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. | 2000 May |
|
Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer. | 2000 May-Jun |
|
Cell cycle status and apoptosis of hematopoietic progenitor cells released into the peripheral blood after taxanes and granulocyte colony-stimulating factor in breast cancer patients. | 2000 May-Jun |
|
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. | 2000 Sep |
|
A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: a prospective study in patients with ovarian cancer. | 2000 Sep-Oct |
|
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. | 2001 |
|
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. | 2001 |
|
In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry. | 2001 |
|
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts. | 2001 Apr |
|
Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition. | 2001 Apr 26 |
|
Phytochemistry and medicinal plants. | 2001 Feb |
|
Selective drug resistant human osteosarcoma cell lines. | 2001 Feb |
|
Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. | 2001 Feb |
|
Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan. | 2001 Jan |
|
Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation. | 2001 Jan |
|
Colchicine and griseofulvin inhibit VCAM-1 expression on human vascular endothelial cells - evidence for the association of VCAM-1 expression with microtubules. | 2001 Jan |
|
Opposite effects of microtubule-stabilizing and microtubule-destabilizing drugs on biogenesis of mitochondria in mammalian cells. | 2001 Jan |
|
Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers. | 2001 Jan |
|
CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. | 2001 Jan 1 |
|
Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. | 2001 Jan 15 |
|
Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. | 2001 Jan 15 |
|
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. | 2001 Jan 15 |
|
Dispersion of cyclin B mRNA aggregation is coupled with translational activation of the mRNA during zebrafish oocyte maturation. | 2001 Jan 15 |
|
The role of actin filaments and microtubules in hepatocyte spheroid self-assembly. | 2001 Mar |
|
Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle. | 2001 Mar 1 |
|
Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. | 2001 Mar 12 |
Patents
Sample Use Guides
For previously untreated patients with carcinoma of the ovary, one of the following recommended regimens may be given every 3 weeks.
a.TAXOL (PACLITAXEL) administered intravenously over 3 hours at a dose of 175 mg/m2 followed by cisplatin at a dose of 75 mg/m2; or
b.TAXOL (PACLITAXEL) administered intravenously over 24 hours at a dose of 135 mg/m2 followed by cisplatin at a dose of 75 mg/m2
2) In patients previously treated with chemotherapy for carcinoma of the ovary, the recommended regimen is TAXOL (PACLITAXEL) 135 mg/m2 or 175 mg/m2 administered intravenously over 3 hours every 3 weeks.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27420038
Paclitaxel inhibited tubulin polymerization in the presence of MAPs in vitro with an IC50 value of 38.19 ± 3.33 uM in living cancer cells (Hela cells and human osteosarcoma U2OS cells).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
270208
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
50190
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
NDF-RT |
N0000175085
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
LIVERTOX |
NBK548093
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
394813
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
NCI_THESAURUS |
C67437
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/06/422
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
454014
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
WHO-VATC |
QL01CD01
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
594217
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
469915
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
103497
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
186404
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
482015
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
NDF-RT |
N0000175592
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
278309
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
384912
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
104797
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
454114
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
PAXENE (WITHDRAWN: OVARIAN NEOPLASMS)
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
CFR |
21 CFR 516.1684
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
290709
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
252907
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
NCI_THESAURUS |
C1490
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
WHO-ATC |
L01CD01
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
ABRAXANE (AUTHORIZED: PANCREATIC NEOPLASMS)
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
291009
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
PAXENE (WITHDRAWN: CARCINOMA, NON-SMALL-CELL LUNG)
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
141701
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
||
|
FDA ORPHAN DRUG |
280409
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
33069-62-4
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
100000085474
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
P88XT4IS4D
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
EE-62
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
45863
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
D017239
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
6839
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
125973
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
CHEMBL428647
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
DTXSID9023413
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
DB01229
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
2770
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
P88XT4IS4D
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
7052
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
PACLITAXEL
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
1491332
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
56946
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
SUB09583MIG
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
C1411
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
36314
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
M8351
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | Merck Index | ||
|
Paclitaxel
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
C495179
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
2044
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
PRIMARY | |||
|
486610
Created by
admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
|
ALTERNATIVE |
ACTIVE MOIETY
METABOLITE (PARENT)
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)